Search

everythinglearnresearchcommunity

for

Search:↓

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

Hair/scalp cloning for unlimited transplants is likely a decade away, with prior transplants not significantly affecting future options. Advances in AI and research in wound-induced hair neogenesis are promising, but infrastructure and technology constraints remain challenges.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

The hair transplant at Eugenix in New Delhi resulted in poor density and texture, with only about 2,500 grafts surviving out of 4,500. The user is considering holding the clinic accountable and exploring options like shaving, using hair fibers, or seeking another transplant.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.

Hair cloning may become available in 1-2 years in Japan, but widespread availability and affordability could take 7-15 years. Current treatments like finasteride are effective but may lose effectiveness over time.

The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

Finasteride helped OP recover their hairline, and they did not use minoxidil. OP experienced significant hair regrowth with finasteride, similar to their father's experience.

The conversation is about using topical melatonin or zix for hair loss without affecting hormones. The user is seeking advice on which treatment is more effective.

A 39-year-old from Bangalore shared his successful hair transplant journey, which included 3537 scalp and 1521 beard grafts, boosting his confidence. He also started medication alongside the transplant.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

The user experienced significant hair regrowth over 10 months by using 1.5mg oral finasteride and minoxidil daily, along with weekly derma stamping, after a previous hair transplant and initial thinning. The conversation highlights the importance of using DHT blockers post-transplant to maintain results.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The user experienced significant hair regrowth using a combination of minoxidil, finasteride, various serums, and micro-needling, leading to increased confidence and consideration of a hair transplant. Despite initial baldness due to past health issues, the user is pleased with the progress and continues to use treatments like Pilgrim, Md Hair, Bodywise Roller, and Bouf serums.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.